Analysis indicates aminopenicillins may remain effective for ampicillin-resistant enterococcus UTIs, suggesting viability.
Urinary tract infections (UTIs) caused by Enterococcus species are a frequent clinical challenge. The rising prevalence of ampicillin resistance often seemingly precludes the use of aminopenicillins. However, evidence suggests that aminopenicillins may retain clinical efficacy, even when susceptibility testing indicates resistance. Integrating available pharmacokinetics/pharmacodynamics and clinical data and risk-benefit considerations, we seek to address the question: Can aminopenicillins still be a viable treatment option in the management of ampicillin-resistant Enterococcus infections?
No takes yet. Share an insight, caveat, or question.
Hawes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: